UCB and Biogen reported encouraging topline findings from the Phase III PHOENYCS GO trial, which assessed dapirolizumab pegol, a novel Fc-free anti-CD40L drug candidate, in individuals with moderate-to-severe SLE. The promising outcomes with dapirolizumab pegol […]
The European Commission has granted conditional approval for Ipsen’s IQIRVO (elafibranor) for the treatment of primary biliary cholangitis in adults, marking the first new therapy for this condition to be approved in the EU in […]
The hormone replacement therapy market is witnessing substantial growth due to the rising occurrence of hormonal and targeted conditions such as menopause and osteoporosis, coupled with the growing elderly population, which is fueling demand for […]
The axial spondyloarthritis market is experiencing robust growth due to increasing awareness and advancements in treatment options. Rising prevalence rates and a growing focus on personalized medicine are driving market expansion, with innovative therapies and […]
The CEACAM5 drugs market is expected to grow significantly in the coming years. This is due to the increasing number of patients being diagnosed with cancer and the increasing number of CEACAM5 that are under […]
